# Jerrold H. Levy

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jerrold-h-levy/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,004 |
| Field | Trauma, Hemostasis, Coagulopathy, Resuscitation |
| h-index | 95 |
| i10-index | 414 |
| Last Known Institution | Duke University |
| OpenAlex ID | https://openalex.org/A5053864173 |
| ORCID iD | 0000-0003-3766-4962 |
| Works | 755 |

## Researcher papers

Showing 12 of 13.

- [COVID-19 and its implications for thrombosis and anticoagulation](https://scholariq.org/papers/covid-19-and-its-implications-for-thrombosis-and-anticoagulation/)
- [Coagulation abnormalities and thrombosis in patients with COVID-19](https://scholariq.org/papers/coagulation-abnormalities-and-thrombosis-in-patients-with-covid-19/)
- [Idarucizumab for Dabigatran Reversal](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal/)
- [Guidelines for Perioperative Care in Cardiac Surgery](https://scholariq.org/papers/guidelines-for-perioperative-care-in-cardiac-surgery/)
- [Idarucizumab for Dabigatran Reversal — Full Cohort Analysis](https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal-full-cohort-analysis/)
- [Thromboinflammation and the hypercoagulability of COVID‐19](https://scholariq.org/papers/thromboinflammation-and-the-hypercoagulability-of-covid-19/)
- [Safety of Recombinant Activated Factor VII in Randomized Clinical Trials](https://scholariq.org/papers/safety-of-recombinant-activated-factor-vii-in-randomized-clinical-trials/)
- [Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19](https://scholariq.org/papers/scientific-and-standardization-committee-communication-clinical-guidance-on-the/)
- [Patient Blood Management](https://scholariq.org/papers/patient-blood-management/)
- [Coagulopathy in COVID‐19](https://scholariq.org/papers/coagulopathy-in-covid-19/)
- [A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting](https://scholariq.org/papers/a-multicenter-double-blind-placebo-controlled-trial-of-aprotinin-for-reducing/)
- [Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery](https://scholariq.org/papers/levosimendan-in-patients-with-left-ventricular-dysfunction-undergoing-cardiac/)

## Researcher topics

- [Trauma, Hemostasis, Coagulopathy, Resuscitation](https://scholariq.org/topics/trauma-hemostasis-coagulopathy-resuscitation/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Blood transfusion and management](https://scholariq.org/topics/blood-transfusion-and-management/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Heparin-Induced Thrombocytopenia and Thrombosis](https://scholariq.org/topics/heparin-induced-thrombocytopenia-and-thrombosis/)

## Researcher university

- [Duke University](https://scholariq.org/institutions/duke-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.